Kardigan, Inc. is a clinical-stage biotechnology company. The company is focused on developing precision medicines to treat and functionally cure specific cardiovascular diseases. Kardigan's primary investigational pipeline includes three major drug candidates: danicamtiv is a potential first-in-class cardiac myosin activator designed to directly activate both atrial and ventricular function. It is being developed to treat genetic dilated cardiomyopathy (DCM) driven by sarcomeric mutations....